Vascular Biology of Reactive Oxygen Species and NADPH Oxidases: Role in Atherogenesis

Adrian Manea

1"Petru Poni" Institute of Macromolecular Chemistry, Iasi
2"Nicolae Simionescu" Institute of Cellular Biology and Pathology, Bucharest
Romania

1. Introduction

Eukaryotic cells face constantly the formation of reactive oxygen species (ROS) as a result of their aerobic metabolism. ROS play an important role in the regulation of signal transduction pathways and gene expression but its over-production is acutely harmful to cells, particularly in cardiovascular diseases (CVD) by a mechanism that is not fully understood. Most CVD (the leading cause of mortality in developed countries) entail the focal development of atherosclerotic plaques in response to various deleterious insults that affect the artery wall’s cells (Simionescu, 2007). Atheroma may occlude partially or totally the arterial lumen and ultimately, rupture of the vulnerable plaques results in thrombus formation and obstruction of the vessels of vital organs like heart, brain, lung, and kidney. Atheroma formation is characterized by progressive lipid accumulation in the vessel’s intima, dysfunctions of endothelial cells (EC) and smooth muscle cells (SMC), and a strong inflammatory reaction with the participation of extravasated immune cells (Fearon & Faux, 2009). Compelling evidence (including ours) revealed that oxidative stress and NADPH oxidase - derived ROS play the key role in all stages of atherosclerosis and that genetic ablation of various oxidase components protects the cells against the detrimental effects of oxidative stress (Simionescu et al., 2009). Therefore, understanding the molecular mechanisms of ROS formation and function is a prerequisite of an effective anti-oxidative stress therapy.

2. Reactive oxygen species formation in the vasculature

As the name indicates, ROS are a class of highly reactive molecules derived from chemical conversion of molecular oxygen (O_2). ROS are formed in all the aerobic cells and organisms as by-products of metabolic and respiration processes, under the influence of ionizing radiation or produced deliberately by specialized enzyme systems. ROS formation is initiated by reduction of O_2 with one electron leading to the formation of short-lived and highly reactive superoxide anion (O_2•−). Successive reduction of O_2•−, protonation or interaction with various converting enzymes gives rise to a large spectrum of molecules with diverse physicochemical characteristics such as H_2O_2 and HO•. The dismutation of O_2•− to H_2O_2 can be either spontaneous or catalyzed by specialized enzymes namely, members of the superoxide dismutase family. H_2O_2 may be completely reduced to H_2O by
means of various peroxidases such as catalase and glutathione peroxidase or partially reduced to HO•, one of the most powerful oxidizing agent identified in biological systems. The generation of HO• is mediated by various free transition metal ions (e.g., Fe^{2+}, Cu^{2+}) via the Haber-Weiss reaction (Manea, 2010).

Apart from the aforementioned chemical processing of O\(_2\), superoxide can react with other molecular species including nitrogen species such as nitric oxide (NO) or polyunsaturated fatty acids. The reaction between O\(_2\)^•• and NO is tightly controlled by the rate of diffusion of both radicals, and result in the formation of ONOO•- a potent oxidant. Alternative reactions may led to the generation of mixed reactive oxygen and nitrogen radicals such as nitrogen dioxide radical (•NO\(_2\)) and nitryl chloride (NO\(_2\)Cl) (Turrens, 2003).

Lipid peroxidation products formation represents an important mechanism whereby ROS elicit physiological and pathophysiological function in the living cells. ROS (especially HO•, •NO\(_2\), and ONOO•-) may react with polyunsaturated fatty acids present on biological membranes or circulating/infiltrated lipoproteins, a condition that facilitate the formation of fatty acid peroxy radical (R-COO•-) that can further attack adjacent fatty acid chains and trigger the production of other lipid radicals by a chain reaction mechanism (Negre-Salvayre et al., 2010; Riahi et al., 2010; Shao & Heinecke, 2009).

Tyrosyl radicals produced by myeloperoxidase (MPO) have also been shown to be involved in the initiation of lipid peroxidation (Hazen et al., 1997). *In vitro* studies revealed that lipid peroxidation occurred only in the presence of free L-tyrosine suggesting that tyrosyl radicals formation by MPO are essential mediators for the initiation of lipid peroxidation and subsequent LDL oxidation by activated human neutrophils, which contain abundant MPO and H\(_2\)O\(_2\) (Savenkova et al., 1994). Tyrosyl radicals have also been shown to play a role in LDL oxidation *in vivo* and in atherogenesis. Analysis of LDL isolated from human vascular tissue demonstrated that o,o'-dityrosine levels were 100 times greater than that observed in circulating LDL. Similarly, o,o'-dityrosine formation was found to be robust increased in atherosclerotic fatty streaks and in advanced atheromas compared to normal aortic tissue, indicating that tyrosyl radical formation was capable of protein damage *in vivo* (Leeuwenburgh et al., 1997).

### 3. Molecular targets of ROS

The biological function of ROS is highly regulated by their basic physicochemical properties, cellular compartmentalization and the formation rate. Since O\(_2\)^•• is a short-lived charged species, it cannot diffuse through biological membranes and acts closely of the formation site. Nevertheless, an anion channel-dependent plasma membrane transport mechanisms has been demonstrated to play an important role in mediating cell-to-cell communication. Notably, O\(_2\)^•• is water-soluble and functions either as an oxidizing agent (e.g., one-electron reduction of O\(_2\)^•• yields H\(_2\)O\(_2\)) or as a reducing agent (e.g., ONOO• formation). HO• is extremely reactive and does not diffuse more than that a few molecular diameters from its site of formation (Touyz, 2003). In contrast, H\(_2\)O\(_2\) is highly stable under physiological conditions. Being an uncharged molecule, H\(_2\)O\(_2\) is membrane-permeable and able of activating downstream signalling molecules relatively far from the site of formation.

At low, physiological concentration, ROS modulate key signalling processes initiated by hormones, cytokines, vasoactive agents, blood coagulation factors, and hemodynamic shear stress. Reactive oxygen intermediates react at near-diffusion rate and influence the activity of numerous of signalling molecules including receptors, protein kinases/phosphatases,
transcription factors, peptides, ion channels and transporters, lipids, carbohydrates, and other oxygen-based species, a process that influence dramatically the cell behavior (Shao & Heinecke, 2009). The affinity of ROS for a specific substrate is dictated by both physicochemical features of the reactive oxygen intermediates and also of the targeted molecules. In addition, the occurrence and the abundance of specific functional groups, such as iron-sulfur centers, disulfide-bonds, amino and hydroxyl groups or fatty acids double-bonds, greatly influence the chemical interactions between ROS and redox-sensitive biological molecules. As initially showed in microorganisms, eukaryotic cells respond to increased generation of O$_2^•$- and H$_2$O$_2$ by the up-regulation of various gene products, largely antioxidant enzymes and molecules implicated in the preservation of cellular homeostasis, self-renewal, and reparatory processes. In terms of selectivity, O$_2^•$- reacts preferentially with the transcription factors and electron transporters in respiratory chains containing iron-sulfur clusters. In contrast, H$_2$O$_2$ reacts mainly with the disulfide-bonds present on the protein kinases/phosphatases, transcription factors, and ion channels. Additional compelling evidence highlights that the redox-regulation of cell function represents an evolutionary conserved mechanism that alter directly or indirectly the activities of a large spectrum of signaling molecules (Liu et al., 2005).

Protein tyrosine phosphatases (PTPs) are probably the best characterized signaling molecules targeted directly by ROS, especially of H$_2$O$_2$, owing to the existence of a highly conserved 230-amino-acid domain that contains reactive cysteine, which catalyzes the hydrolysis of protein phosphotyrosine residues. Consequently, a key mechanism whereby H$_2$O$_2$ controls various cellular processes is determined by the reversible oxidation of PTPs catalytic cysteines that blocks protein dephosphorylation causing transient inhibition of PTPs.

Notably, several members of the protein tyrosine kinases (PTKs) family, including non-receptor protein tyrosine kinases (i.e., Src, Jak, Pyk) have been shown to be activated in response to cellular redox variations (Tonks, 2006). Nevertheless, the precise molecular mechanisms of PTKs redox regulation are not entirely understood, and it is not clear if the PTK activities are directly correlated with the alterations induced by ROS action on enzyme structures Still, most of the available date suggests that the majority of the effects are attributable to PTP inhibition by ROS rather than PTK oxidation (Tabet et al., 2008).

Another important class of molecules regulated by redox-dependent mechanisms is represented by the mitogen-activated protein kinase (MAPKs) family, that control key physiological processes such as mitosis, differentiation, proliferation, cell survival, and apoptosis. MAPKs are serine/threonine-specific protein kinases which activities are tightly regulated by complex phosphorylation pathways. Emerging evidence demonstrates that in the cardiovascular system, the functions of MAPKs are also influenced by extracellular and intracellular ROS by yet incompletely defined mechanisms (Wu et al., 2008). Apparently, the upstream regulators of MAPKs, namely MAPK kinases (MEKs), PTKs, and PTPs, might be the actual molecular targets of ROS and the genuine sensors of the intracellular redox state changes (Sedeek et al., 2009).

Similar to PTPs, MAPK phosphatases (MKPs) display a highly conserved redox-sensitive cysteine in their catalytic core. Thus, the oxidative inhibition of MKPs may results in the persistent activation of MAPKs, as observed in various developmental or pathological states. Taken together, redox-dependent and as well as redox-independent activation of MAPKs cascades congregate to activate downstream signaling pathway in response to
hormones, growth factors, pro-inflammatory mediators, and vasoactive agents. Besides MAPKs, the activity of serine/threonine protein kinases Akt and Rho has been indicated to be redox-sensitive and to play a central role in cellular survival pathways (Lee & Griendling, 2008). Apart from protein kinases/phosphatases and transcription factors, ROS are important regulators calcium homeostasis, by mechanisms that engages reversible thiol oxidation of the cysteine residues present on ion channels and transporters. In the vascular cells ROS, particularly $\text{O}_2^{\cdot -}$ and $\text{H}_2\text{O}_2$, also enhance intracellular $\text{Ca}^{2+}$ concentrations by increasing the extracellular influx through the plasma membrane channels and mobilization from intracellular stores, and by the inhibition of Ca$^{2+}$-ATPases located in the plasma membrane and endoplasmic reticulum. The plasma membrane K$^+$ channels have been shown to be redox-sensitive, a process that mediates hyperpolarization-dependent vascular relaxation (Belia et al., 2009; Briones & Touyz, 2010). These data indicates that the redox status of ion channels and transporters plays an essential role in cell physiology and represents an important determinant of vascular pathology under conditions of the altered production of ROS.

4. Antioxidant mechanisms in the cardiovascular cells

ROS are physiologically produced at low concentration during metabolic processes in non-phagocytic cells, by the mitochondrial respiratory chain, cyclooxygenases, lipoxygenases, cytochrome P450 reductase, xanthine oxidase. Almost three decades ago, the commonly accepted assumption was that the antioxidant system has developed to defend the cells against the damaging and unavoidable effects of ROS, which are capable to produce irreversible, structural, and functional oxidative damage of DNA, proteins, lipids, and carbohydrates. This theory was supported by many experimental evidence regarding the strategic tissular distribution, expression/concentration levels, and localization of the antioxidants within cellular compartments. Nevertheless, soon after the discovery of enzyme systems that deliberately generates ROS (e.g., NADPH oxidases) under physiological and pathological states, it has become apparent that ROS are not just the by-products of aerobic metabolism, but also important signalling molecules (Forman et al., 2010; Go & Jones 2010). Therefore, the subtle relationship among oxidizing and reducing agents permits ROS to function as second messengers and to regulate various cellular functions. Thus, besides neutralization of ROS, the antioxidant system has emerged as a critical regulator of the redox-sensitive processes. The concentration of various oxygen-based reactive intermediates is maintained in physiological range by a very complex antioxidant system comprising both enzymatic ROS scavengers, namely superoxide dismutase, catalase, glutathione peroxidase, thioredoxin, glutaredoxin, peroxiredoxin, heme oxygenase, and paraoxonase, and non-enzymatic ROS quenchers, such as glutathione, vitamins, lipoate, urate, and ubiquinone (Zadák et al., 2009). Superoxide dismutases (SOD) represent a family of enzymes that catalyze the dismutation of $\text{O}_2^{\cdot -}$ into $\text{O}_2$ and $\text{H}_2\text{O}_2$. Three SOD isoforms are expressed concomitantly in different cellular compartments, including the cytosol (SOD1; Cu/ZnSOD), mitochondria (SOD2; MnSOD), and the extracellular space (SOD3; ecSOD) (Valdivia et al., 2009). Catalase (CAT) is found in peroxisomes where it decomposes $\text{H}_2\text{O}_2$ to $\text{H}_2\text{O}$ and $\text{O}_2$. Glutathione peroxidases (GPx) represent a family of isoenzymes encoded by separate genes that differ in cellular distribution pattern and substrate specificity. GPx1, the most abundant isoform, is expressed in the cytosol and has $\text{H}_2\text{O}_2$ as its main substrate. GPx2 is an extracellular space enzyme,
while GPx3 is particularly abundant in the plasma. GPx4 has as substrates lipid hydroperoxides and is present at a low level in nearly every cell type. Thioredoxins (TRx) and glutaredoxins (GRx) are proteins that function as antioxidants by enabling the reduction of other proteins by cysteine thiol-disulfide exchange. Apart from being involved in antioxidant defense, different isoforms of the TRx and GRx families have been shown to play an important role in regulation of gene expression by redox-dependent processes. Peroxiredoxins (PRx) represent a ubiquitous family of antioxidant enzymes whose activities are tightly regulated by phosphorylation cascades and by changes in the redox and oligomerization states. PRx controls intracellular peroxide levels and mediate signal transduction in cardiovascular cells (Woo et al., 2010).

5. Role of oxidative stress in atherogenesis

Physiological production of ROS contribute to the preservation of vascular homeostasis by regulating important biological processes such as cell growth, proliferation, differentiation, apoptosis, cytoskeletal organization, and cell migration. Still, in the last few decades, it has become apparent that overproduction of ROS correlated with alterations of the antioxidant system, vascular inflammation and metabolic dysfunction are key pathological initiators of cardiovascular disorders. Generated in excess, ROS react randomly with all of biological molecules inducing the irreversible alterations of DNA, proteins, carbohydrates, and lipids components, thus altering cell functions (Martinet et al., 2001). As a result, extensive studies have concentrated on the role of oxidative stress-induced cellular dysfunction, redox control of vascular response to inflammatory and metabolic insults, the molecular mechanisms of ROS generation and the means that this class of molecules contributes to vascular damage. Oxidative stress represents a pathological condition characterized by the incapacity of antioxidant mechanisms to neutralize the deleterious effects of ROS and their metabolites. The means of oxidative stress onset and progression in vascular pathological states, include the overproduction of ROS, changes in the endogenous antioxidant system, and the production of various oxygen intermediates such as ONOO− and HO• that cannot be efficiently buffered by the naturally occurring antioxidant mechanisms. In addition, spatial and temporal co-expression and co-localization of various enzymatic and non-enzymatic ROS-producing sources at the site of vascular insults may potentially exacerbate predispose to vascular insults and dysfunction (Kondo et al., 2009; Lee et al., 2009).

The importance of oxidative stress in onset and development of atherosclerosis is commonly accepted (Fearon & Faux, 2009). Still, numerous clinical trials failed to demonstrate that the antioxidant therapy improve the health of patients with cardiovascular diseases (Yusuf et al., 2000). Consequently, many questions arise relative to our current knowledge of the molecular processes implicated in ROS formation and action. Hitherto, different pharmacological approaches have been employed to counteract oxidative stress-induced injury in the cardiovascular system i.e. antioxidant supplements containing vitamins C and E, polyphenols or selective inhibitors of distinct sources of ROS (Olukman et al., 2010). Nevertheless, these pharmacological interventions have many disadvantages such as inadequate concentration of active compounds at the site of ROS formation, or vitamins themselves becoming radicals with pro-oxidant activity or not being effective scavengers for various reactive oxygen/nitrogen intermediates, namely hydrogen peroxide (H2O2), peroxynitrite anion (ONOO−), hydroxyl anion (HO•), and hypochlorous acid (HOCl).
Excessive ROS formation in atherogenesis triggers a chain of critical events such as EC dysfunction, oxidation of macromolecules especially LDL and extracellular matrix constituents, phenotypic alterations of SMC and macrophage/SMC-derived foam cell and modulate the function of signalling molecules in fibroblasts, which promotes inflammation of vascular adventitia (Sima et al., 2009). Vascular resident cells and transvasated immune cells are important sources of ROS within the atheroma (Heistad et al., 2009). These particularities show that atherosclerosis represents a multifactorial vascular disorder characterized by complex interactions and cross talk between the resident cells of the vascular wall, the cells of the immune system and the factors they produce.

As shown in various animal models of atherosclerosis, oxidative stress is a primary occurrence and a key contributor to endothelial dysfunction portrayed by diminished endothelial NO bioavailability, enhanced endothelial transcytosis, up-regulation of pro-inflammatory molecules, and the alteration of EC fibrinolytic activity (Dejana et al., 2009; Vendrov et al., 2007). In addition, oxidation of macromolecules especially of LDL (oxLDL) plays a key role in all stages of atherogenesis such as fatty streak formation, development of complex lesion, and plaque rupture. Of particular importance is that oxidative stress contributes, at least in part in the modulation of SMC phenotype switching and ultimately contributes to artery wall thickening. In atherosclerosis, SMCs undergo hypertrophy, produce excess extracellular matrix and inflammatory cytokines, proliferate and migrate from the media towards the vessel’s intima.

Clinical evidence highlights that oxidative stress is a characteristic feature of many pathological conditions that predispose to atherosclerotic lesion formation such as hypercholesterolemia, hypertension, and diabetes. However, the precise pathological mechanisms accountable for the installation of oxidative stress are still an unsettled subject. In this context, although not completely validated in humans, oxidative stress may not be the sole causative effect of atherosclerosis and one has to consider the diversity of enzymatic and non-enzymatic sources of ROS, their vascular distribution pattern and subcellular compartmentalization, and complex regulation during various stages of the disease progression (Förstermann, 2008).

6. Vascular sources of ROS: Role of NADPH oxidases

Various pathways of ROS generation that can potentially contribute to oxidative stress have been described in the cardiovascular system including non-enzymatic decomposition of various compounds and metabolites (e.g., glucose autoxidation), production of ROS as byproducts of cellular respiration and metabolism (i.e., mitochondrial respiratory chain, lipo-/cyclooxygenases, dysfunctional nitric oxide (NO) synthases, cytochrome P450 reductases, xanthine oxidase), lysosomal enzymes or generated in a highly regulated manner by specialized enzymes (e.g., NADPH oxidases) (Gu et al., 2001; Harrison et al., 2003; Madamanchi et al., 2005; Martinez-Hervas et al., 2010; Zalba et al., 2007).

NADPH oxidases (Nox) represent a family of multi-component enzymes, whose unique biological function is the production of ROS both in physiological and pathological states (Lambeth, 2004). Nox was originally identified and characterized as being a “burst” enzyme in professional phagocytes such as neutrophils and macrophages. In phagocytes, in cooperation with MPO, Nox plays a major role in host defense process against invading pathogens through the production of toxic hypochlorous acid (HOCl), a highly reactive oxidant. During phagocytosis, macrophages also generate significant amounts of NO. As a
result, the Nox-derived $\text{O}_2^{-}$ reacts with NO thus producing ONOO$^{-}$, an extremely cytotoxic chemical species which directly affect and oxidize biological molecules in invading microorganisms, resulting in molecular alteration and microbial death (El-Benna et al., 2007). The phagocyte-type Nox consists of five subunits: a membrane-associated cytochrome b558, comprising a heavily glycosylated 91-kDa protein (gp91phox; Nox2) and non-glycosylated 22-kDa subunit (p22phox), and three cytosolic regulatory components, p40phox, p47phox, and p67phox. Besides “Phox” components, assembly of Nox in an active complex requires the contribution of a low-molecular-weight GTP-binding protein, Rac1/2 or Rap 1A. In latent cells, the Nox complex is dissociated but is rapidly assembled and activated following the exposure to pathogens or inflammatory mediators. Serine phosphorylation of p47phox represents the limiting step of Nox activation and triggers complex formation of cytosolic subunits followed by translocation to the membrane and association with cytochrome b558 (Hoyal et al., 2003; Lassègue & Griendling 2002; Li & Shah 2003). Other than Nox2, macrophages also express Nox1 and Nox4 as inducible isoforms that, reportedly mediate LDL oxidation in the vascular wall (Lee et al., 2009; Maitra et al., 2009).

The expression of functionally active Nox subtypes has been reported in non-phagocytes, including cardiovascular cells. Thus far, the members of the Nox enzyme family consists of seven isoforms (Nox1-5, Duox1/2), each with a particular cell and tissue distribution. Nox enzymes are broadly divided into three major categories, as a function of the extra catalytic domains to the phagocyte-type subunit Nox2. The first group includes Nox1, Nox3, and Nox4 isoforms, which display a number of similarities with Nox2, for instance their structural organization and molecular weight. Besides Nox2-type catalytic core, Nox5, the second group of the Nox family, possess an extra amino-terminal calmodulin-like domain that contains four Ca$^{2+}$-binding EF-hands structures (Lambeth, 2007). Thus far, four splice variants of Nox5, namely Nox5α, Nox5β, Nox5γ, and Nox5δ, have been identified in humans. In particular, the Nox5 gene is not present in the rodents’ genome. A third class of Nox is represented by the Nox5-like dual oxidases (Duox) which possess, in addition to the Nox5-type structure, an extracellular peroxidase domain that uses the $\text{H}_2\text{O}_2$ generated by its Nox catalytic core. For their function, all the Nox1-4 subtypes necessitate the p22phox component, while Nox5 and Duox are activated directly by calcium. As shown in aortic SMCs, activation of Nox1 requires the participation of a CIC-3 anion transporter. The anion transporter co-expresses with Nox1 in early endosomes and is required for charge neutralization of the electron flow generated by Nox1 across the membrane of signalling vesicles (Miller et al., 2007). Nox4 is constitutively active and its activity is supported by the association with p22phox, required for the electron transfer, and polymerase delta interacting-protein 2 (Polidp2), that apparently may serve to stabilize the enzymatic complex (Lyle et al., 2009). The activities of Nox1, Nox2, and Nox3 isoforms are highly controlled by phosphorylation reactions involving regulatory subunits that initiate the assembly of Nox into an active enzymatic complex. Other than p40phox, p47phox, and p67phox cytosolic regulatory components, two different structurally related proteins have been discovered in non-phagocyte, specifically Nox organizer 1 (Noxo1), which is an analog of p47phox, and Nox activator 1 (Noxa1), which is an analog of p67phox. Despite the structural similarities, dissimilar functional aspects are involved in the regulation of enzyme activity. For instance, different to p47phox, which in the resting cells is located in the cytosol, Noxo1 is pre-localized at the membrane jointly with Nox1 and p22phox (Lambeth,
2004). Different subtypes of the Nox enzyme family along with their regulatory proteins are expressed in the cardiovascular cells (i.e., ECs, SMCs, vascular and cardiac fibroblasts, cardiac myocytes, and pericytes), and in circulating immune cells interacting with the blood vessels (i.e., monocytes/macrophages, neutrophils, lymphocytes, platelets, dendritic cells) (Manea et al., 2005).

Nox subtypes are differentially located within the cellular compartments, suggesting a specific correlation between Nox subtypes, subcellular distribution and their specific function to control precise ROS-mediated signal transduction cascades. For instance, Nox1 and Nox2 were detected in caveolae, in the plasma membrane, and endosomes. Nox4 has been detected in focal adhesions, mitochondria endoplasmic reticulum, and the nucleus (Ago et al., 2010; Kuroda & Sadoshima, 2010). Nox5 is present in the perinuclear regions, endoplasmic reticulum, and in the plasma membrane (BelAiba et al., 2007; Fulton, 2009).

7. Involvement of Nox enzymes in atherogenesis

Studies in cell culture and transgenic/knockout mice provided most of the existing data concerning the role of Nox-dependent oxidative stress in atherosclerosis. Nox activity is up-regulated by numerous factors linked to atherosclerotic lesion formation and progression namely, inflammatory cytokines (tumor necrosis factor α, interferon γ), vasoactive agents (angiotensin II, endothelin 1), metabolic factors (high glucose, modified proteins/lipoproteins/lipids, homocysteine), growth factors (platelet-derived growth factor), coagulation factors (thrombin), and pathological shear stress (Chung et al., 2010; Hwang et al., 2003). Apart from direct detrimental effects, compelling data exists that Nox-derived ROS interact and stimulate other enzymatic sources of oxygen/nitrogen reactive intermediates, and generally amplify the initial response to insults (Cohena & Tong, 2010; Schrader & Fahimi, 2006).

It is generally accepted that Nox-derived ROS cooperate, and act in concert with other pathological factors leading to vascular inflammation and injury, and that genetic ablation of various Nox subunits (i.e., p47phox, Nox1, Nox2) defends the vascular cells against the harmful effects of oxidative stress. ApoE/-/- mice, which develop atherosclerotic lesions that cover the entire range of human lesions (i.e., fatty streaks, intermediate lesions, fibrous plaques, and vulnerable plaques exhibiting necrotic core and intra-plaque hemorrhage) have been extensively used to investigate the role of Nox enzymes in atherogenesis (Nakashima et al., 1994). Using this animal model, it has become evident that enhancements in Nox activity and expression occur early in atherosogenesis, and hyperactivity of Nox associated with the up-regulation of various isoforms marks all the stages of the plaque formation (Fenyo et al., 2011).

In contrast, ApoE/p47phox double-knockout mice display significantly less atherosclerotic lesions compared with ApoE/-/- mice. In the same line, aortic $O_2^\cdot-$ levels have been shown to be are lower in p47phox/-/- mice than in wild-type mice. In addition, aortic SMCs from p47phox/-/- mice exhibit a decreased proliferative response to growth factors compared with that of the SMCs of wild-type mice (Vendrov et al., 2007).

Accelerated atherosclerosis represents a major vascular complication of diabetes mellitus and is responsible for 70-80% of deaths in diabetic patients in developed and developing countries. Numerous reports revealed that the Nox expression and activity are significantly up-regulated in the vasculature of diabetic subjects, and are associated with the
development of atherosclerosis and microvascular diseases (retinopathy, neuropathy, and nephropathy). In addition, Nox1, Nox2, and Nox4 are activated and up-regulated in the blood vessels of diabetic animals (Ding et al., 2007; Xu et al., 2007).

Hyperglycemia, the primary clinical manifestation of diabetes, contributes at least in part to diabetic complications by inducing Nox and the ensuing oxidative stress. Moreover, advanced glycation end-products (AGEs), a direct consequence of the high and persistent blood glucose level, are also important inducers of Nox-derived ROS in vascular cells in diabetes. Besides hyperglycemia, hyperinsulinemia contribute to aberrant ROS production and vascular wall dysfunction. Since Nox is one of the main triggers of oxidative stress, it has a prominent role in the pathology of diabetes-induced vasculopathy (Gao & Mann, 2009). These data make Nox enzymes potential therapeutic targets to counteract the deleterious effects of ROS in diabetes.

Hypertension represents a major risk factor for atherosclerosis and its complications and several reports highlight that oxidative stress is both cause and consequence of hypertension (Briones & Touyz, 2010). Nox1 deficiency in mice reduces angiotensin II (Ang II)-dependent blood pressure, media hypertrophy, and extracellular matrix deposition, but not cell proliferation (Gavazzi et al., 2007; Matsuno et al., 2005). In agreement with these data, AngII-treated mice overexpressing Nox1 in vascular smooth muscle cells exhibit an increase of blood pressure, a condition that is associated with medial hypertrophy and significant production of ROS (Dikalova et al., 2005). Furthermore, overexpression of Nox1 in vascular SMCs leads to enhanced responsiveness to Ang II causing up-regulation of ROS, eNOS uncoupling and the consequent decline in NO bioavailability, followed by impaired vascular relaxation (Dikalova et al., 2010).

Consistent with these reports, compared with wild-type mice, Nox2 ablation (Nox2-/-) diminishes robustly ROS-mediated protein oxidation, neointimal formation, SMCs proliferation and leukocyte accumulation, indicating that Nox2-mediated signalling and oxidation has a requisite role in the cell response to injury (Chen et al., 2004).

The role of Nox4 and Nox5 enzymes in atherogenesis is less investigated and consequently, not entirely elucidated, since there are few atherosclerosis-related studies conducted on Nox4 deficient mice, and the Nox5 gene is not present in the rodent's genome. Thus, most of the current data are provided by studies performed in vitro on various cell-types and isolated tissues.

Recently, a Nox4 deficient mouse model and a cardiomyocyte-targeted Nox4-transgenic model have been developed to investigate the role of Nox4 during cardiac stress. (Zhang et al., 2010). One of the main breakthroughs of this study is that in contrast to the effects of generated by activated Nox1 or Nox2, the up-regulation cardiomyocyte Nox4 results in protection against pressure overload-induced adverse cardiac remodeling. The authors conclude that Nox4 facilitates the maintenance of myocardial capillary density during pressure overload by regulating stress-induced cardiomyocyte hypoxia inducible factor-1 activation and release of vascular endothelial growth factor, resulting in increased paracrine angiogenic activity. In addition, unlike Nox1, Nox2 or Nox5, it seems that Nox4 produces directly H2O2 and thus is incapable of scavenging NO or producing ONOO-. The beneficial effects of Nox4-derived ROS were also reported by means of a newly developed transgenic mouse with endothelial-specific Nox4 overexpression (Ray et al., 2011). The authors showed that vascular segments and endothelial cells of these animals had
a significant increase in \( \text{H}_2\text{O}_2 \) generation rather than \( \text{O}_2^{•−} \) and a significant augmentation of the pro-oxidative status. Despite of these aspects, the blood pressure of the animals was lower under basal conditions and after angiotensin II treatment. Interestingly, endothelium-dependent relaxation was significantly improved compared with wild-type animals. Notably, these effects were sensitive to the ex vivo addition of catalase and in vivo administration of \( N \)-acetylcysteine, indicating that they were mediated by peroxide-type, namely \( \text{H}_2\text{O}_2 \), mechanisms. Mechanistically, it seems that an \( \text{H}_2\text{O}_2 \) action on potassium channels may be responsible for the elaboration of endothelium-derived hyperpolarizing factor (EDHF) type. Thus, one has to ponder that the type of ROS released in the vascular system determines their biological function.

As mentioned above, less is know about the role of Nox5 in atherogenesis, and this is due mainly to the absence of Nox5 gene in the rodents’ genome and therefore to the lack of a reliable animal model. Still, it has been reported a significant correlation between Nox5 expression and atherosclerotic lesion progression. Interestingly, a specific expression pattern was reported; with Nox5 being expressed mainly by the endothelium in the early stages of the disease while its expression is significantly increased in SMCs underlying fibro-lipid atherosclerotic lesions (Guzik et al., 2008).

8. Mechanisms of Nox regulation

8.1 Phosphorylation pathways and transcription factors

Nox activity and expression is highly regulated at multiple levels by various physiologic and pathological factors which, by this means, dictate the enzyme complex function. The activities of both Nox1 and Nox2 isoforms are primarily regulated by complex networking of phosphorylation cascades involving regulatory components (i.e., p40phox, p47phox, p67phox, Noxo1, Noxa1) which induce the assembly of the enzyme complex. Nox4 is constitutively active and does not necessitate phosphorylation of regulatory proteins, whereas Nox5 has been demonstrated to be \( \text{Ca}^{2+} \)-responsiveness. Yet, activation mechanisms involving protein kinase C and the proto-oncogenic tyrosine kinase c-Abl phosphorylation of Nox5 have been reported (El Jamali et al., 2008; Serrander et al., 2007).

The phosphorylation mechanisms responsible for Nox1 and Nox2 activation consist of a large spectrum of signalling molecules such as protein kinase C (PKC), phosphatidylinositol 3-kinase (PI3K), GTP-binding proteins (Ras, Rac1/2), members of the mitogen-activated protein kinase (MAPK) family (p38MAPK, ERK1/2), phospholipases (PLC\( \gamma \), PLD), arachidonic acid metabolites, and non-receptor protein tyrosine kinases (Kilpatrick et al., 2010; Yamamori et al., 2004). Besides the aforementioned kinases, chaperone proteins (e.g., protein disulfide isomerase) have been proved to be important regulators on Nox function (Janiszewski et al., 2005).

In addition to the phosphorylation of cytosolic regulatory subunits, alterations of the Nox isoforms expression have been shown to be critical for their activity. Multiple transcription factors are coordinately implicated in the modulation of Nox expression and function. PU.1, Elf-1, IRF-1 (interferon regulatory factor-1), and ICSBP (interferon consensus sequence binding protein) are important transcriptional regulators of Nox2 in the myelomonocytic cell lineage (Kakar et al., 2005). In human colon epithelial Caco-2 cells, GATA-binding factors are critical for Nox1 transcriptional activity (Brewer et al., 2006), whereas in murine macrophages, the up-regulation of Nox1 in response to lipopolysaccharide (LPS)
stimulation is mediated at least in part, by pro-inflammatory transcription factors CCAAT/enhancer-binding protein (C/EBP)β and C/EBPδ (Maitra et al., 2009). In previous studies, we have shown that in human aortic SMCs exposed angiotensin II or tumor necrosis factor-α, the pro-inflammatory transcription factor AP-1 is an essential regulator of the genes coding for p22phox, Nox1, and Nox4 components (Manea et al., 2008; Raicu & Manea, 2010). Other than, activator protein 1 (AP-1), the vascular inflammation-related and growth-promoting transcription factors signal transducer and activator of transcription (STAT1 and STAT3) proteins physically interact with the promoters of human Nox1 and Nox4 genes in SMCs exposed to interferon (IFN) γ and a Janus kinase (Jak)/STAT-dependent mechanisms are implicated in the ensuing O₂•⁻ production. Moreover, the promoter activities of the genes coding for p22phox, p47phox, and p67phox, have been demonstrated to be considerably augmented in SMCs overexpressing STAT1/STAT3, a result that suggests the existence of functionally gamma activated sequence (GAS)/interferon-stimulated response element (ISRE) consensus sequences (Manea et al., 2010a). In human aortic SMCs, Ets1, a critical mediator of vascular inflammation and remodelling, regulates p47phox expression in response to AngII (Ni et al., 2007). Similar observations were made in A7r5 cells and primary mouse aortic SMCs, in which the growth-promoting transcription factor E2F actually interacts and controls the Nox4 transcriptional program (Zhang et al., 2008).

In atherosclerosis, and other major cardiovascular disorders, nuclear factor kB (NF-kB) signalling represents a critical regulating mechanism involved in disease onset and progression, including inflammation, cell proliferation, migration, differentiation and apoptosis. Several line of evidence indicate that NF-kB is a redox-sensitive transcription factor which is robustly activated by ROS possible generated by activated Nox. Interestingly, a positive feed-back loop of Nox activation by NF-kB has been proposed in several studies. Thus, a new integrative concept has emerged the “vicious cycle”, to describe the interconnection between metabolic dysfunction, inflammation, and oxidative stress that converges to vascular disorders (Manea, 2010). In murine monocytes, the expression of the Nox2 is induced by NF-kB. Moreover, the up-regulation of p47phox and p22phox expression by LPS/IFNγ was blunted in IkBα-overexpressing cells suggesting the involvement of the NF-kB signaling in the regulation of the Nox components (Anrather et al. 2006). Similar finding were reported in human monocytes/macrophages exposed to TNFα (Gauss et al., 2007). Moreover, in previous studies we have shown that, NF-kB is an important transcriptional regulator of the genes coding for p22phox, Nox1, and Nox4, and has a profound impact in the up-regulation of Nox activity in TNFα-treated human aortic SMCs (Manea et al., 2007; Manea et al., 2010b).

The molecular mechanisms that facilitate hypoxia sensing and related signalling events are critical for the maintenance of vascular cell homeostasis. Compelling data depicts that hypoxic conditions up-regulate the expression and activity various Nox subtypes (Goyal et al., 2004). It has been demonstrated that persistent hypoxia induces Nox4 gene and protein expression levels in pulmonary artery SMCs and in pulmonary vessels in mice exposed to hypoxic conditions (Diebold et al., 2010). Mechanistically, the response is dependent on hypoxia inducible factor-1α (HIF-1α), which interacts with the corresponding elements in the Nox4 promoter. As a result, the HIF-1α dependent up-regulation of Nox4 by may be an essential mechanism to preserve ROS level after hypoxia and the hypoxia-induced proliferation of pulmonary artery SMCs. Furthermore,
activating transcription factor-1 (ATF-1), a transcription factor of the CREB (CRE-binding protein)/ATF family, proved to play a key role in the induction of Nox1 in rat vascular SMCs (Katsuyama et al., 2005). Nuclear factor (erythroid-derived 2)-like 2, also known as Nrf2 represents a master modulator of the antioxidant responses by inducing genes (e.g., Sod genes) with important function in combating oxidative stress. Interestingly, it has been demonstrated that Nrf2, also controls Nox4 expression in mouse lung and human lung endothelium in response to hyperoxia (Pendyala & Natarajan, 2010).

8.2 Genetic and epigenetic mechanisms of Nox regulation

Genetic studies highlight that several Nox-related polymorphisms are closely associated with an increased susceptibility for cardiovascular disorders. One of the most investigated genes from the Nox complex is CYBA which encodes the p22phox essential subunit. The p22phox is ubiquitously expressed in cardiovascular cells and forms stable and functional heterodimers with Nox1, Nox2 or Nox4, a critical structure for enzyme activity as shown by studies employing siRNA technology to knock-down p22phox expression (Kawahara et al., 2005). Moreover, it has been demonstrated that p22phox is more abundant in advanced atherosclerotic plaques than in nonatherosclerotic arteries, suggesting a correlation between p22phox expression, \( \text{O}_2^{\cdot-} \) production, and the severity of atherosclerosis (Azumi et al., 1999).

The occurrence of particular polymorphisms of the CYBA gene has been shown to predispose to oxidative stress and to be independently correlated with cardiovascular risk factors and disease occurrence namely hypertension, coronary artery disease, myocardial infarction, cerebrovascular disease, diabetic and non-diabetic nephropathy) (San José et al., 2008). Various CYBA allelic variants were detected in both exonic sequences such as C242T, A640G, C549T (Dinauer et al., 1990; Guzik et al., 2000; Inoue et al., 1998), and promoter regions namely -930A/G, -675A/T, -852C/G, -536C/T (Lim et al., 2006; Moreno et al., 2007), which potentially affect the p22phox expression and consequently the Nox activity. Thus far, data indicating the existence of functional Nox1-5 polymorphisms with a relevant impact on vascular pathology are not available yet.

Emerging evidence demonstrates that epigenetic events such as DNA methylation and modifications of histone tails are important processes of oxidative stress onset. DNA methylation mechanisms of the promoter CpG islands has been shown to be involved in the up-regulation of 15-lipoxygenase, a pro-oxidative enzyme with implications in plaque formation and vulnerability, and down-regulation of superoxide dismutase 3, endothelial NO synthase, and various anti-proliferative genes (estrogen receptor-\( \alpha \)), a condition that leads to oxidative stress, impaired vascular relaxation, and aberrant SMC hyperplasia (Fernandez et al., 2010). Hitherto, data about the role of epigenetics in the regulation of Nox subtypes are missing. Nevertheless, using both in vitro (e.g., human aortic SMCs exposed to pro-inflammatory conditions) and in vivo (ApoE-/- mice fed a high fat, cholesterol rich diet) models, we have found recently that an aberrant methylation of the Nox1 promoter may be responsible for the up-regulated expression and activity of this enzyme (Manea et al., unpublished data).

A schematic representation of the key molecular pathways implicated in the up-regulation of Nox enzymes as well as the potential pharmacological targets intended to counteract oxidative stress are presented in the figure below.
Fig. 1. Schematic depiction of the major mechanisms responsible for the up-regulation of Nox enzymes and installation of oxidative stress in atherosclerosis. In response to cardiovascular risk factors, vascular cells through their receptors activate a range of signalling pathways that up-regulate Nox expression, activity, and the ensuing ROS production. This triggers a chain of critical events that generally amplify the initial response to vascular insults (i.e., activation of other cellular sources of ROS and redox-sensitive signalling effectors). Persistent Nox activation leads to oxidative stress that is a major contributor to the initiation and the development of atherosclerotic lesions. The diagram highlights that genetic, epigenetic, as well as genetic/non-epigenetic-independent mechanisms linked to Nox up-regulation and hyperactivity in atherosclerosis may be used to target and control pharmacologically the Nox-derived oxidative stress (green text).

9. Conclusion

The Nox-derived ROS may have both beneficial and deleterious effects. Thus, we can safely assume that these effects are function of the expression pattern and regulation of various Nox isoforms, their subcellular compartmentalization, and the rate of ROS generation. Despite of the numerous existing data, the precise mechanisms of Nox regulation in atherosclerosis and the stream of signalling molecules (up-, or down-regulated) responsible for the increased oxidative stress that is associated with the onset and development of cardiovascular dysfunction, is poorly understood. Thus, a complex interplay of genetic, epigenetic and non-epigenetic factors, transcription factors, co-activators, and/or co-repressors may be coordinately involved in the up-regulation of Nox activity in
Atherogenesis. Therefore, elucidation of the complex interactions among different mechanisms that control Nox subtypes expression/activity and subcellular compartmentalization of ROS production and its subsequent biological meaning, may lead to a more focused and effective antioxidant therapies. The expected impact of these pharmacological strategies goes well beyond the atherosclerosis field. Oxidative stress is a common occurrence in most pathologies i.e. diabetes, neurodegenerative diseases, cancer, etc. The knowledge gained will be applicable to all these pathologies since controlling oxidative stress ought to have a beneficial knock-on effect on these diseases. Identifying the basic molecular mechanism regulating the oxidative stress will be used to find ways to manage its occurrence and correct its adverse effects.

10. Acknowledgement

This work was supported by grants from the Romanian Ministry of Education, and Research (CNCSIS-UEFISCSU project numbers PNII-IDEI 1005/2009 and PNII-TE 65/2010), and from the European Foundation for the Study of Diabetes - New Horizons. The financial support of European Social Fund – “Cristofor I. Simionescu” Postdoctoral Fellowship Programme (ID POSDRU/89/1.5/S/55216), Sectoral Operational Programme Human Resources Development 2007 – 2013 is acknowledged.

11. References


www.intechopen.com


Atherogenesis


Maitra, U., Singh, N., Gan, L., Ringwood, L. & Li, L. (2009) IRAK-1 contributes to lipopolysaccharide-induced reactive oxygen species generation in macrophages by inducing NOX-1 transcription and Rac1 activation and suppressing the expression of antioxidative enzymes. Journal of Biological Chemistry, 284, 35403-35411, ISSN ISSN 0021-9258


role of p22phox subunit. *Arteriosclerosis Thrombosis and Vascular Biology, 28*, 878-885, ISSN 1079-5642


synthase and NADPH oxidase expressions. *Journal of Diabetes and its Complications*, 24, 415-423, ISSN 1056-8727


phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circulation Research, 103, 149-158, ISSN 0009-7330


This monograph will bring out the state-of-the-art advances in the dynamics of cholesterol transport and will address several important issues that pertain to oxidative stress and inflammation. The book is divided into three major sections. The book will offer insights into the roles of specific cytokines, inflammation, and oxidative stress in atherosclerosis and is intended for new researchers who are curious about atherosclerosis as well as for established senior researchers and clinicians who would be interested in novel findings that may link various aspects of the disease.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:
